We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
'Progressive MS - macro views': The need for novel clinical trial paradigms to enable drug development for progressive MS.
- Authors
Zaratin, P.; Comi, G.; Leppert, D.
- Abstract
This article outlines the principal challenges to establish a standard phase-2 approach for progressive multiple sclerosis (PMS) and presents referring strategies to accelerate the registration process via a guidance approved by regulatory agencies. Accordingly, the contribution of 'big datasets' for a better understanding of the natural history of primary-progressive multiple sclerosis (PPMS) and secondaryprogressive multiple sclerosis (SPMS) and of their prognostic factors and the value of novel biomarkers are discussed. The establishment of new industry-academic initiatives, such as independent consortia under the umbrella of Progressive MS Alliance (PMSA), with the endorsement of MS organizations and Scientific Societies (e.g. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)) may be crucial to overcome some of the current challenges. Within this frame, the continuous interaction with regulatory agencies is instrumental for the formal validation of the many developments suitable to improve clinical trialling in PMS.
- Subjects
MULTIPLE sclerosis treatment; MULTIPLE sclerosis; ACADEMIC-industrial collaboration; CLINICAL trials; HEALTH outcome assessment; PROGNOSIS
- Publication
Multiple Sclerosis Journal, 2017, Vol 23, Issue 12, p1649
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/1352458517729457